"The voice for cancer physicians and their patients in Massachusetts."

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 15 Feb 2018 9:18 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved apalutamide (Erleada; Janssen) for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Read full press release. 

  • 08 Feb 2018 2:12 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved abiraterone acetate (Zytiga, Janssen Biotech, Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). Read full press release.

  • 12 Jan 2018 1:20 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to olaparib tablets (Lynparza; AstraZeneca) a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Read full press release. 

  • 08 Jan 2018 2:32 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, nivolumab (Opdivo; Bristol-Myers Squibb) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Read full press release.

  • 08 Jan 2018 2:25 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug administration granted regular approval to pertuzumab (Perjeta; Genentech) for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. Read full press release.

  • 28 Nov 2017 9:43 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to obinutuzumab (Gazyva; Genentech) in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II buly; III, or IV follicular lymphoma (FL). Read full press release.

  • 17 Nov 2017 7:39 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved emicizumab-kxwh (Hemlibra; Genentech) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congential factor VIII deficiency) with factor VIII inhibitors. Read full press release. 

  • 16 Nov 2017 11:00 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to brentuximab vedotin (Adcetris; Seattle Genomics) for the treatment of adult-patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systematic therapy. Read full press release. 

  • 16 Nov 2017 10:53 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to dasatinib (Sprycel; Bristol-Myers Squibb) for the treatment of pediatric patients with Philadelphia chromosome-positive (PH+) chronic myeloid leukemia (CML) in the chronic phase. Read full press release.

  • 16 Nov 2017 10:46 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to alectinib (Alecensa; Genentech) for the treatment of partients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. Read full press release. 

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

Upcoming events

  • No upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software